Original article / research
A Retrospective Analysis of the Efficacy of Ceftriaxone-Sulbactam-EDTA Combination for Suspected Biofilm Infections
Dr. Sunita Gupta,
Department of Medicine, Maharishi Markandeshwar Institute of Medical Sciences and Research,
Mulana, Ambala-133207, Haryana, India.
Introduction: Bacterial biofilms are highly recalcitrant to antibiotic treatment and thus carry important clinical repercussions. In view of rising biofilm-forming pathogens, new antibacterial approaches aimed at disrupting biofilms are needed.
Aim: To determine the clinical utility of CSE-1034 (Ceftriaxone-Sulbactam-EDTA) therapy in suspected biofilm infections.
Materials and Methods: Subjects with Urinary Tract Infections (UTIs) or Intra-Abdominal Infections (IAIs) with in-vivo devices (catheters, stents, etc.,) and suspected of biofilm-related infections and who received CSE-1034 as 2nd line therapy were included in this study. Based on susceptibility report, CSE-1034 therapy was started in these patients and continued or discontinued based on improvement in clinical symptoms.
Results: Thirty culture-positive adult patients were included in this study. All the patients had received Pipericillin-Tazobactam (Pip-Taz) or Cefaperazone-Sulbactam empirically but none of them responded clinically. Culture susceptibility results available on day 3 have shown that isolates from 40% patients started with Pip-Taz were reported susceptible to Pip-Taz and 45% of patients started with Cefaperazone-Sulbactam were reported susceptible to antibiotic used. 100% of the isolates were susceptible to CSE-1034, 90% to Meropenem and susceptibility to Colistin was 80%. Based on culture susceptibility report and further treatment modifications done, all the patients were switched over to CSE-1034 as 2nd line treatment. A total of 27 patients responded to CSE-1034 and were cured. However, 3 patients who did not respond to CSE-1034 for 48 hour were switched over to Meropenem and reported to be cured.
Conclusion: From this study, it can be suggested that CSE-1034 should be a choice of treatment over beta-lactam/beta-lactam inhibitor combinations for patients suspected of biofilm infections.
|[ FULL TEXT ] | [ ]|